News & Media

Life sciences industry expected to hit $1.5-T milestone by 2022

Health care digitization and consumerization, a tsunami of patient data and the emergence of value-based reimbursement models are shaking things up in this ever-evolving industry. The convergence of biopharmaceuticals, drug delivery devices, and companion diagnostics is driving regulatory and commercial changes that make this a very exciting time, according to Frost & Sullivan’s recent analysis, Global Life Sciences Industry Outlook, 2018.

Back

Subscribe to the BAM Newsletter

Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.

Subscribe